Play a critical role in Transcatheter Mitral & Tricuspid Therapies (TMTT) clinical study execution including leading the internal specialist training program and maintain an audit ready environment by ensuring compliance with all physician and training procedures, maintain drive high
Working with Us Challenging. Meaningful. Life-changing. Those aren’t words that are usually associated with a job. But working at Bristol Myers Squibb is anything but usual. Here, uniquely interesting work happens every day, in every department.
Join us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by
We exist to create positive change for people and the planet. Join us and make a difference too! Location: Germany The base salary for this position starts from 56 000 Euro gross annually The role: Youll
Play a critical role in Transcatheter Mitral & Tricuspid Therapies (TMTT) clinical study execution including leading the internal specialist training program and maintain an audit ready environment by ensuring compliance with all physician and training procedures, maintain drive high
The Edwards Transcatheter Aortic Heart Valves unit (THV) consists of our SAPIEN family of transcatheter aortic and pulmonic heart valves which are the most widely prescribed transcatheter heart valves in the world! Edwards leadership in transcatheter
Patients with mitral and tricuspid heart valve disease often have complex conditions with limited treatment options. Our Transcatheter Mitral and Tricuspid Therapies (TMTT) business unit is boldly pursuing an innovative portfolio of technologies to address a
Make a meaningful difference to patients around the world. Driven by a passion to help patients live healthier and more productive lives, our Field teams embrace Edwards Lifesciences values to build trusting, lasting relationships with medical
Patients with mitral and tricuspid heart valve disease often have complex conditions with limited treatment options. Our Transcatheter Mitral and Tricuspid Therapies (TMTT) business unit is boldly pursuing an innovative portfolio of technologies to address a